Vera Therapeutics (VERA) Free Cash Flow (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Free Cash Flow data on file, last reported at -$106.5 million in Q1 2026.

• Quarterly Free Cash Flow fell 95.12% year-over-year to -$106.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$293.7 million (down 87.75% YoY) and the FY2025 annual result came in at -$241.7 million, down 78.2% from the prior year.
• Free Cash Flow eased to -$106.5 million in Q1 2026, from -$70.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$9.0 million in Q1 2022 to a low of -$106.5 million in Q1 2026.
• A 5-year average of -$37.9 million and a median of -$26.3 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 236.58% — and 2023, when it gained 6.65%.
• Tracing VERA's Free Cash Flow over 5 years: stood at -$21.2 million in 2022, then decreased by 19.11% to -$25.2 million in 2023, then slumped by 58.0% to -$39.8 million in 2024, then plunged by 76.0% to -$70.1 million in 2025, then plunged by 51.97% to -$106.5 million in 2026.
• The last three Free Cash Flow figures came in at -$106.5 million (Q1 2026), -$70.1 million (Q4 2025), and -$62.0 million (Q3 2025), per Business Quant data.